E-viri
Recenzirano
-
VanderWeele, David J; Hussain, Maha
NEJM evidence 1, Številka: 9Journal Article
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown therapeutic success for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency. Preclinical data suggest that PARP inhibitors may have efficacy in a wider population if combined with androgen receptor inhibition. One phase 2 trial for late-stage mCRPC supports this notion, finding that olaparib added to abiraterone/prednisone improved radiographic progression-free survival (PFS) versus abiraterone/prednisone alone in a population that was not biomarker preselected. However, another trial with abiraterone and veliparib did not show benefit. .
